CytoImmune Therapeutics

We are excited to have this support from Roche. Expanding our Phase 1 trial to CSSIFM will also allow us to extend this promising therapy to more patients.

This milestone underscores the progress we are making towards our mission of developing next-generation cancer therapies. Our leading candidate continues to advance through clinical trials, bringing us closer to delivering new treatment options to patients. We're grateful for the financing Banco Popular initially provided, which helped accelerate our progress. We look forward to expanding our strategic partnerships with other cell therapy and biologics companies looking to capitalize on our team's development expertise and Puerto Rico's unique tax incentives.

Our CEO Jose Eduardo Vidal interviews with host Eric Michaels and discusses the following: What is gene and cell therapy and how does it work? What conditions can be treated with cell therapy? What is the difference between treatment therapy and curative therapy? What is the difference between chemo/radio therapy and immunotherapy for cancer? When will cell therapy be available to patients? What are the limitations?

Exciting news from the frontlines of #CellTherapy! CytoImmune Therapeutics has recently acquired a license to the ALPPL2 portfolio from Flame Biosciences, marking a significant stride towards potentiating the development of novel #CancerTherapies. This acquisition adds a new layer of versatility to our therapeutic arsenal by integrating a range of highly specific, targetable tumor cell surface antigens that could result in multiple orphan drug designations. It solidifies our standing as a critical collaborator in the evolving landscape of #Biotech, pushing the envelope of innovation in the allogeneic cell therapy sector. The ALPPL2 portfolio exhibits a spectrum of therapeutic technologies, inclusive of chimeric antigen receptor T cells, #NaturalKillerCells, antibody drug conjugates (ADC), bispecific, and monoclonal antibodies - underscoring its potential to impact a broad range of solid tumors. Our manufacturing facility in Toa Baja, Puerto Rico, armed with proprietary NK cell expansion and engineering technologies, is primed to deliver on the promise of the ALPPL2 portfolio. CytoImmune’s commitment to leveraging advanced technologies enables us to break through conventional boundaries and deliver unparalleled cell therapy solutions to our partners. Looking forward to seeing how this integration will drive the development and commercialization of next-generation #NKCellTherapies and shape the future of cancer treatment. Stay tuned for more updates on this transformative development. #BioPharma #Innovation #CancerResearch #CytoImmuneTherapeutics

We at CytoImmune Therapeutics are thrilled to announce a new chapter in our growth story – we're expanding our services to now encompass cell therapy development and manufacturing. Our team’s deep-rooted experience in working with T cells and Natural Killer (NK) cells allows us to modify these cells to express various gene products. The result? Enhanced survival, targeted cytotoxicity, and improved antibody dependent cellular cytotoxicity - opening up new possibilities for patient treatments. This expansion positions us as a critical partner for biotech companies aiming to innovate in the field of cell therapy. We understand the challenges of setting up cGMP manufacturing facilities, and we're here to support you every step of the way - from discovery to first-in-human trials. Our state-of-the-art clinical cell manufacturing facility is ready to assist with the analytical and process development and clinical manufacturing of cutting-edge T cell and NK cell therapies. This exciting expansion underlines our commitment to foster partnerships that fuel the future of cell therapy and transform cancer patients’ lives. We're excited about what this means for our clients and for the wider autologous and allogeneic cell therapy industry. We thank you for being a part of our journey and look forward to bringing life-changing treatments to those in need, together. #CellTherapy #Biotech #HealthcareInnovation #CytoImmune

Following the company’s successful development of a genetically modified NK cell product for lung cancer, now in clinical trials, Dr. Vidal is extending our company’s reach by offering cell therapy development and clinical manufacturing services to biotechnology companies.